Harnessing AI and omics for next-generation gene therapy manufacturing

“To make AI and ML truly effective, it is essential to integrate domain-specific knowledge.”Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Richard D Braatz, Chief Scientist and Co-founder of BioCurie, and Irene Rombel, CEO and Co-founder of BioCurie, about their work in AI-driven software and omics technologies to optimize gene therapy production. They discuss the untapped opportunities in integrating omics data, improving efficiencies, and leveraging AI to enhance therapeutic accessibility.